IOVA

6.9005.61%
RK

Raj K. Puri

Chief Regulatory Officer

Dr. Raj K. Puri MD, Ph.D,for more than 19 years, Dr. Puri has served as the director of the Division of Cellular and Gene Therapies (DCGT) in the Office of Tissues and Advanced Therapies at the United States Food and Drug Administration (FDA) in its Center for Biologics Evaluation and Research. He is also a Chief of Tumor Vaccines and Biotechnology Branch within DCGT. He served as Executive Vice President, Regulatory Strategy and Translational Medicine at Iovance Biotherapeutics, Inc. since March 2022 until November 2024 and serves as its Chief Regulatory Officer since November 22, 2024. Dr. Puri joined Iovance Biotherapeutics, Inc. in March 2022. During his working at the FDA, Dr. Puri held various positions as a reviewer and laboratory chief prior to his service as a division director. Dr. Puri has experience with the evaluation and regulation of advanced therapies including cell and gene therapy, cancer vaccines and cellular immunotherapy. As a principal investigator and throughout his career, Dr. Puri has led research in the field of cancer therapies, including agents such as immunotoxins, cancer vaccines and T cells including chimeric antigen receptor-modified T cells and tumor infiltrating lymphocytes. Dr. Puri trained at the National Cancer Institute’s Surgery Branch, where he worked in the laboratory of Dr. Steven Rosenberg on adoptive immunotherapy approaches for cancer and at the Mayo Clinic, Rochester, Minnesota where he worked on progesterone hormone receptors. He received his M.D. from the University of Juarez Medical School Institute of Biosciences and his Ph.D. in Medical Sciences from the Central Drug Research Institute, Lucknow.

Positions